Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 74.1%

Neg 0% Neu 0% Pos 74.1%

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.